Acute myeloid leukemia

Researchers are testing a new cell therapy called anti-FLT3 CAR-T (HG-CT-1) in adults and children with acute myeloid leukemia (AML) that has come back or stopped responding to standard treatment. The study is a Phase 1 dose-escalation trial, meaning its first goal is to find out…

Older adults with acute myeloid leukemia (AML) often fare poorly with chemotherapy alone, and a stem cell transplant can offer better long-term survival but carries a high risk of transplant-related death. Researchers are comparing two drug combinations given before a haploidenti…

This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard treatment. The therapy uses a patient's own natural killer (NK) cells, engineered to re…

This study tests a new approach to prevent leukemia from coming back after a stem cell transplant. It uses donor T cells that have been engineered to recognize and attack a specific target (HA-2) on leukemia cells. The trial enrolls adults with acute myeloid leukemia (AML) or mye…

This trial is testing whether adding bortezomib to standard chemotherapy (CPX-351) can improve outcomes for people with a newly diagnosed, aggressive form of acute myeloid leukemia that has a TP53 mutation. The study aims to find a safe dose and see if the combination leads to mo…

This program gives patients with certain blood cancers access to Orca-T, a donor stem cell therapy, when the commercial version cannot be used. It is for people who have no other treatment options. The program monitors safety but does not test if the therapy works.

This study tests whether adding pivekimab sunirine to the standard drugs venetoclax and azacitidine helps adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. About 660 participants will be randomly assigned to receive ei…

This phase 2 trial tests whether a once-weekly oral combination of decitabine-cedazuridine and venetoclax is safer and as effective as standard therapy for people with relapsed or refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, or high-risk myeloproliferati…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This early-stage trial tests two oral drugs, ziftomenib and quizartinib, together in adults with relapsed or hard-to-treat acute myeloid leukemia (AML) that has certain genetic markers. The goal is to find a safe and effective all-pill treatment for common AML subtypes. About 44 …

Researchers are testing whether adding an experimental drug called RVU120 to venetoclax can help adults with acute myeloid leukemia (AML) that has come back or stopped responding to earlier venetoclax-based treatment. The trial enrolls about 98 adults who have already failed a hy…

This study tests whether two drugs, venetoclax and revumenib, can control minimal residual disease (MRD) in people with acute myeloid leukemia (AML). MRD means small numbers of cancer cells remain after initial treatment, raising the risk of relapse. The trial enrolls about 8 par…

This study tests whether adding the drug venetoclax to standard chemotherapy can better treat acute myeloid leukemia (AML) that is newly diagnosed or has come back. About 116 adults with AML or high-risk MDS will receive the combination. The goal is to see if the combo improves r…

This phase II trial tests whether adding gilteritinib to the usual two-drug therapy (azacitidine and venetoclax) can help older or frail adults with a specific type of acute myeloid leukemia (FLT3-mutated) achieve deeper remission. About 147 participants will be randomly assigned…

This phase II trial is testing whether adding the drug venetoclax to standard chemotherapy can improve remission rates in younger patients with intermediate-risk acute myeloid leukemia (AML). About 153 participants will receive either standard chemo or a combination with venetocl…

This phase 2 trial is testing a combination of five drugs (fludarabine, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin) in 270 people with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome that have specific genetic changes. The goal…

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This phase II trial tests whether adding enasidenib to standard ASTX727 and venetoclax improves remission rates in older adults (or younger unfit patients) with newly diagnosed IDH2-mutated acute myeloid leukemia (AML). About 93 participants will be randomly assigned to receive e…

This early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…

This phase II trial tests several experimental drug combinations against the standard treatment for high-risk acute myeloid leukemia (AML) in patients aged 59 or younger. The goal is to see if newer regimens, including venetoclax and liposome formulations, can better shrink cance…

This study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…

This phase I trial tests a new treatment for adults with acute myeloid leukemia (AML) who have minimal residual disease (MRD) — small amounts of cancer cells that remain after standard therapy. The treatment uses the patient's own T cells, genetically modified to recognize a prot…

This large phase 3 trial is testing whether a new formulation of two chemotherapy drugs (CPX-351) and a targeted drug called gilteritinib can improve outcomes for children and young adults with newly diagnosed acute myeloid leukemia (AML). The study compares these new approaches …

This phase 2 trial tests whether adding the targeted drug venetoclax to standard chemotherapy is safe and effective for children and young adults (up to age 22) with newly diagnosed acute myeloid leukemia (AML). The study aims to see if this combination can reduce the amount of c…

This early-phase trial tests a two-step approach for people with acute myeloid leukemia or related blood cancers that have returned or not responded to treatment. First, patients receive intensive chemotherapy (CLAG-M or FLAG-Ida) followed immediately by a reduced-intensity stem …

This phase 3 trial will test whether adding the drug quizartinib to the standard two-drug combination (venetoclax and azacitidine) helps adults with newly diagnosed acute myeloid leukemia (AML) live longer. The study includes 376 people aged 18 and older who cannot receive intens…

This study tests two different doses of the drug quizartinib as a maintenance therapy for adults with a specific type of acute myeloid leukemia (FLT3-ITD positive) who are in their first complete remission after initial treatment and have not had a stem cell transplant. The goal …

This study tests an oral drug called revumenib in people with certain types of leukemia that have relapsed or not responded to standard therapy. The trial has two parts: first, finding the best dose, then testing that dose in four groups based on leukemia type. About 447 particip…

This early-phase study tests a new type of immune therapy for people with certain blood cancers (leukemias) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells c…

This study tests a new mix of drugs for people newly diagnosed with a specific type of acute myeloid leukemia (AML). The treatment combines a targeted drug (venetoclax) with two chemotherapy drugs, then switches to another chemo drug plus venetoclax. The goal is to see if this ap…

This study tests an experimental drug called CGT9486 (bezuclastinib) in people with advanced systemic mastocytosis, a rare and serious blood disorder. The drug aims to control the disease by blocking a key protein that drives abnormal mast cell growth. About 140 adults with aggre…

This early-stage trial is testing an experimental drug called AMX-883, taken by mouth, for people with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. The study will first test AMX-883 alone, th…

This study tests whether using stem cells from both a half-matched family donor and a cord blood donor can improve survival without cancer returning. It is for people with certain high-risk blood cancers like leukemia or myelodysplastic syndromes. The approach aims to control the…

This early-phase trial is testing whether a long-acting antibiotic called dalbavancin, given once every 28 days along with a short course of oral antibiotics, can prevent serious bloodstream infections in children and young adults with high-risk leukemia. The study will enroll 29…

This early-stage study tests an oral drug called AUTX-703 in 34 adults with relapsed or hard-to-treat acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The main goal is to check safety and find the right dose. It's an open-label trial, meaning everyone knows they'r…

This study is testing a new drug called BGB-11417 (sonrotoclax) in people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. The drug works by blocking a protein that helps cancer cells survive. The trial will give the drug alone or toge…

This early-phase trial tests whether giving patients a special infusion of donor immune cells (with certain T and B cells removed) after a stem cell transplant is safe and can help prevent their blood cancer from coming back. The study enrolls high-risk patients with hard-to-trea…

This phase II study is testing a combination of two drugs, enasidenib and azacitidine, in people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial enrolls 50 adults with a specific IDH2 gene mutation. The goal is to see if the combinati…

This study tests a medicine called Xolatryp in adults who have had a severe heart attack (STEMI) and are getting a procedure to open blocked arteries. Participants receive either a single 6-hour infusion of Xolatryp or a placebo, and their heart health is monitored for 30 days. T…

This study tests a combination of three drugs—ivosidenib, venetoclax, and azacitidine—in people with blood cancers like acute myeloid leukemia (AML) that have a specific IDH1 mutation. The goal is to see if the combo is safe and works better than current treatments. About 96 adul…

This early-phase trial is testing a new drug called Debio 1562M in about 134 people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The study first checks safety and finds the right dose, then looks at whether the drug can shrink the can…

This early-phase study tests a new drug called rezatapopt combined with the standard drug azacitidine in 24 adults with a specific type of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has a TP53Y220C mutation. The main goal is to check safety and find the b…

This study is testing whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant, can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) while still being effective. The trial involves 260 adults with b…

This phase 2 trial tests a drug called olutasidenib combined with other targeted therapies for people with relapsed or hard-to-treat blood cancers that have a specific IDH1 mutation plus other signaling mutations. The study aims to see how safe and tolerable these drug combinatio…

This study tests a standardized, optimized approach to cord blood transplantation for adults with high-risk blood cancers like leukemia and lymphoma. The method includes specific chemotherapy, radiation, and stem cell dosing, followed by careful monitoring. Researchers hope to im…

This study tests a daily pill called olutasidenib given after a stem cell transplant to people with certain blood cancers (like AML or MDS) that have an IDH1 mutation. The goal is to see if the drug is safe and tolerable as maintenance therapy. About 31 participants will take the…

This study tests a combination of two drugs, venetoclax and azacitidine, in about 100 adults in India with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for standard intensive chemotherapy. The goal is to see if the combo can put the cancer into remissio…

Researchers are testing an experimental drug called LP-108, a BCL-2 inhibitor, combined with azacitidine in adults with acute myeloid leukemia, myelodysplastic syndromes, or chronic myelomonocytic leukemia. The trial aims to find the highest dose people can tolerate and the best …

This study tests a combination of three drugs—olutasidenib, decitabine, and venetoclax—in people with acute myeloid leukemia (AML) that has a specific IDH1 gene mutation. The goal is to find a safe and effective dose for those whose cancer has returned or not responded to treatme…

This study tests an experimental drug called BL-M11D1 combined with either standard chemotherapy or another targeted therapy in 216 adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination is safe and works better at controlling the cancer. …

This Phase 3 trial tests whether adding the drug venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia (AML) or a related high-risk condition. About 650 participants aged 18 to 75 will receive either venetoclax or a placebo alongside chemo. …

This early-stage study is testing an experimental drug called pivekimab sunirine in about 18 children whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The main goals are to check the drug's safety and how it moves through the body. Partici…

This study tests a new treatment for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to standard therapy. The treatment uses specially engineered natural killer (NK) cells designed to recognize and attack cancer cells…

This study tests a drug called Vyxeos in adults with acute myeloid leukemia (AML) whose cancer did not go away after standard chemotherapy. Vyxeos combines two chemo drugs inside a tiny fat bubble (liposome) to deliver them more effectively. The trial will check for side effects …

This early-stage trial is testing a new antibody drug called GEN3018 in people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has come back or stopped responding to treatment. The main goal is to check safety and find the right dose. Up to 78 parti…

This study tests a combination of three drugs—ASTX727, venetoclax, and gilteritinib—for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome that has a FLT3 mutation. The drugs work in different ways to stop cancer cells from growing. The trial aims to f…

This study tests a combination of two drugs, azacitidine and enasidenib, in people with a high-risk blood cancer called myelodysplastic syndrome (MDS) that has a specific genetic change (IDH2 mutation). The goal is to see if the drugs can stop cancer growth and improve outcomes. …

This study tests a new type of immune cell therapy for people with myeloid cancers (like AML or MDS) that have come back or not responded to treatment. The cells are taken from donated cord blood, engineered to better recognize and attack cancer cells, and given after chemotherap…

This early-phase trial is testing a combination of two oral drugs—venetoclax and decitabine/cedazuridine—in children and teens whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. The study aims to find the safest dose and check for early signs tha…

This phase 1 study is testing a combination of three drugs—ziftomenib, venetoclax, and azacitidine—in children and young adults (ages 2 to 21) with acute leukemia that has returned or not responded to treatment. The main goal is to find the safest dose of ziftomenib when given wi…

This study looks at whether giving the drug venetoclax for a shorter time, along with the combination drug ASTX727, works as well as the usual longer course for adults aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemot…

This study screens people with acute myeloid leukemia (AML) for specific genetic markers to assign them to a treatment sub-study with a targeted drug or combination. It aims to improve response rates by personalizing therapy based on each person's cancer profile. The trial enroll…

This study tests a new drug called SLS009, alone or with other medicines, in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also includes newly diagnosed patients with high-risk leukemia. The goal is to see if the drug i…

This pilot study tests the drug olutasidenib, with or without azacitidine, in 25 adults with a specific type of acute myeloid leukemia (IDH1-mutated) that has returned or not responded after venetoclax treatment. The goal is to see if the cancer can be brought into remission. Par…

This study tests whether adding the targeted drug venetoclax to standard chemotherapy before a stem cell transplant can help prevent cancer from returning in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 participants aged 12 to 6…

This phase 3 trial is testing whether adding revumenib, a drug that blocks a protein called menin, to the usual two-drug combination (azacitidine and venetoclax) can improve outcomes for adults newly diagnosed with acute myeloid leukemia (AML) that has a specific genetic change (…

This study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side …

This study tests whether taking two oral medications (decitabine and ivosidenib) together can control acute myeloid leukemia (AML) in patients aged 60+ or those too frail for standard chemo. About 50 participants will take the pills in 28-day cycles until the disease worsens or s…

This trial tests whether the combination of venetoclax and azacytidine works better than the standard chemotherapy regimen of daunorubicin plus cytarabine in adults aged 18 to 64 with newly diagnosed acute myeloid leukemia that has adverse risk features. Participants are randomly…

This early-phase trial tests a new treatment called CD64 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target and attack leukemia cells. The m…

This study tests a combination of a PD-1 inhibitor (camrelizumab), a chemotherapy drug (azacitidine), and donor immune cells (DLI) in 43 adults with acute myeloid leukemia that has returned after a stem cell transplant. The goal is to see if this approach can help patients achiev…

This early-phase trial is testing a new drug called miRisten in 12 adults whose acute myeloid leukemia (AML) has come back or not responded to prior treatments. The drug works by blocking a molecule that helps cancer cells grow. The main goal is to check safety and find the best …

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This study tests a specially engineered donor graft called Orca-Q in children and young adults with blood cancers who need a stem cell transplant. The graft is designed to help the new cells take hold and reduce complications. The trial is currently on hold, but aims to enroll 40…

This phase 3 trial tests whether adding the drug bleximenib to standard chemotherapy helps adults with a certain genetic type of acute myeloid leukemia (AML). About 875 people will get either bleximenib or a placebo alongside chemo, then be followed for 4 years. The goal is to se…

This early-stage trial is testing whether adding high-dose vitamin C (given through an IV) to the usual two-drug combination (azacitidine and venetoclax) is safe and effective for people newly diagnosed with acute myeloid leukemia who cannot handle intensive chemotherapy. About 3…

This early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults whose acute myeloid leukemia has returned or not responded to prior treatment. The main goal is to find a safe dose and check for early signs that the combination might help control t…

This early-phase study tests whether giving specially trained immune cells (CIML NK cells) along with a targeted drug (venetoclax) can safely help prevent acute myeloid leukemia (AML) from coming back. Ten adults with AML who have already received standard treatment will receive …

This early-stage trial is testing an experimental drug called JNJ-95804306 in people with blood cancers like leukemia that have come back or not responded to standard treatments. The study has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors whe…

This study tests a new oral drug called bleximenib for people with acute leukemia that has come back or not responded to treatment. The drug targets specific genetic changes in the cancer cells. The trial has two phases: first to find the safest dose, then to see how well it work…

This study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. The trial enrolls 600 adults aged 18 and older who h…

This phase 3 trial tests whether adding the drug revumenib to standard intensive chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) that has a specific genetic change (NPM1 mutation). About 468 participants will receive either revumenib or a placebo along…

This early-stage trial is testing an experimental drug called JNJ-90189892 in about 155 people with acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) that have come back or not responded to treatment. The study has several parts: first, finding a safe dose of JNJ-90…

This trial tests whether a combination of venetoclax and azacitidine can work as well as or better than standard intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia that has an NPM1 mutation. Participants are aged 18 to 70 and healthy enough for intensiv…

This study tests a drug called ziftomenib in 70 adults with acute myeloid leukemia (AML) who have specific gene changes (NPM1 or KMT2A) and cannot receive standard chemotherapy. Ziftomenib blocks a protein called menin that helps cancer cells grow. The goal is to see if the drug …

This study looks at how well a combination of two drugs—venetoclax (a pill) and azacitidine (an injection)—works for adults newly diagnosed with acute myeloid leukemia (AML), a cancer of the blood and bone marrow. The participants are people who are older or have health issues th…

This early-phase study tests whether adding a new drug called eganelisib to two standard AML medications (venetoclax and azacitidine) is safe for people with acute myeloid leukemia that has come back or not responded to treatment. About 48 adults will take part to find the best d…

This phase II trial is testing whether the drug ivosidenib, taken as a pill, can help prevent relapse in people with acute myeloid leukemia (AML) or myelodysplastic neoplasia (MDS) who have an IDH1 mutation and have recently undergone a stem cell transplant. Participants will sta…

This early-phase study tests a new treatment called CER-1236 for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myelofibrosis) that have not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified…

This study tests a combination of two drugs, CPX-351 and ivosidenib, in about 30 adults with a specific genetic form of acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if the combo can shrink or control the cancer. Participants must have the IDH1 …

This early-phase study is testing two drugs together — alpelisib and pembrolizumab — in people with metastatic breast cancer or melanoma that has spread to the brain or other organs. The main goal is to find a safe dose and see what side effects occur. Up to 50 adults whose cance…

This early-phase trial tests whether adding a menin inhibitor (SNDX-5613) to standard chemotherapy can better control acute myeloid leukemia (AML) in people with certain gene changes (NPM1 or MLL). About 38 newly diagnosed adults will receive the combination to find the safest do…

This early-stage trial tests a new drug called imetelstat combined with two standard chemotherapies for children and teens with acute myeloid leukemia, myelodysplastic syndrome, or juvenile myelomonocytic leukemia that has returned or not responded to treatment. The main goal is …

This early-phase study tests a new drug called eganelisib, given alone or with standard chemotherapy (cytarabine), in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have returned or not responded to prior treatments. The main goals are …

This phase 2 trial tests whether adding metal detoxification drugs (DMSA and Ca-EDTA) to standard therapy can improve outcomes for adults with intermediate- to high-risk acute myeloid leukemia (AML). Researchers believe lowering metal levels in blood and bone marrow may help cont…

This study tests whether giving special 'memory-like' natural killer (NK) cells after a stem cell transplant can help prevent relapse in children and adults with high-risk acute myeloid leukemia (AML). The NK cells come from the same donor as the transplant and are boosted in the…

This phase 2 trial is testing whether a combination of three oral drugs—venetoclax, chidamide, and chiglitazar sodium—can help people with acute myeloid leukemia (AML) that has returned or not responded to previous treatment. The study will enroll about 30 adults with relapsed or…

This early-phase study tests the drug TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or control leukemia. Participants take a daily capsule for up to 2 years, wit…

This early-phase trial is testing two new chemotherapy combinations for children and young adults with acute myeloid leukemia (AML) who are at intermediate or high risk of relapse. The goal is to see if these combinations are tolerable and can achieve similar or better survival w…

This study tests whether adding the drug venetoclax to standard chemotherapy helps children and young adults with relapsed acute myeloid leukemia (AML) live longer. About 130 participants aged 29 days to 21 years will be randomly assigned to receive either chemotherapy alone or c…

This early-stage trial tests a new drug, 8-chloro-adenosine, combined with the existing drug venetoclax in 30 adults with acute myeloid leukemia that has come back or not responded to treatment. The main goal is to check safety and find the best dose. Researchers hope this combin…

This early-stage trial tests a new treatment called QUAIL-100, made from a live weakened bacteria, in children and young adults with high-risk leukemia or myelodysplastic syndrome who have already had a stem cell transplant. The main goal is to check safety and side effects. Only…

This phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) along with filgrastim in children with high-risk acute myeloid leukemia (AML) that has returned or not responded to treatment. All participants have alr…

This study tracks 1,000 heart attack patients to see if adding SuperSaturated Oxygen therapy to standard angioplasty reduces heart muscle damage and improves outcomes. Participants are adults aged 18-80 who had a specific type of heart attack. The goal is to learn if this extra t…

This study tests a new combination of drugs (venetoclax, azacitidine, chidamide, and others) against the standard chemotherapy for adults aged 60-75 with newly diagnosed acute myeloid leukemia (AML). The goal is to see if the new combo leads to more remissions and fewer side effe…

This study tests a targeted radiation technique (TMLI) combined with two chemotherapy drugs before a stem cell transplant in people aged 50 and older with acute myeloid leukemia or myelodysplastic syndrome that has not responded to treatment or has returned. The goal is to see if…

This early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adult…

This study tests a new way to do stem cell transplants for children with blood cancers like leukemia. It uses a half-matched family donor and removes certain immune cells from the donated cells to lower risks. The goal is to see if this method is safe and helps the child's body a…

This pilot study tests whether drinking tea made from soursop leaves can reduce the number of cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) — blood cancers that have not responded to standard treatments. About 20 particip…

This early-phase study tests a new drug (ICP-248) combined with a standard medicine (azacitidine) in people with acute myeloid leukemia or myelodysplastic syndromes. The goal is to find a safe dose and see if the combo helps control the disease. About 266 adults who have not resp…

This early-stage trial is testing a new combination of chemotherapy drugs (thiotepa, busulfan, and fludarabine) followed by a stem cell transplant for people with certain blood cancers like leukemia and myelodysplastic syndrome. The goal is to see if this approach can reduce the …

This study tests whether patients can safely stop the drug tacrolimus earlier than usual after a stem cell transplant. Tacrolimus is given to prevent graft-versus-host disease (GVHD), but newer methods have lowered GVHD risk. The trial will enroll 50 people with blood cancers and…

This phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…

This trial tests whether giving patients special immune cells, called TAA-T, after a stem cell transplant can help prevent high-risk blood cancers like acute myeloid leukemia from coming back. The cells are designed to recognize three common tumor markers and attack any remaining…

This trial is testing whether an experimental drug called PBSS1113, taken as a pill alongside the standard medicine azacitidine, can help people with acute myeloid leukemia (AML) or a related condition called myelodysplastic syndrome (MDS). The study includes adults who have eith…

This study tests whether a targeted drug called gemtuzumab ozogamicin can clear tiny amounts of leukemia that remain after initial treatment in adults with acute myeloid leukemia (AML). The drug works like a smart bomb, attaching to a protein on cancer cells and delivering a chem…

This early-phase trial tests whether injecting special immune progenitor cells (HTLPs) can help the immune system recover faster after a cord blood transplant in adults with blood cancers. Ten participants will receive the injection alongside their transplant. The goal is to see …

This trial is testing whether a chemotherapy combination called HAD, given at intermediate doses, works better than the standard regimen for people with a specific genetic subtype of acute myeloid leukemia (AML) known as CEBPA double-mutated. The study enrolls adults aged 14 to 5…

This trial is testing whether combining various chemotherapy and targeted drugs can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who are in remission but still have traces of leukemia cells. The study enrolls patients aged 14 and older with …

This trial is testing several different drug combinations to find the best approach for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The study compares the effectiveness and safety of these salvage therapies, aiming to improve rem…

This study tests a new combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as the first treatment for adults with newly diagnosed acute myeloid leukemia (AML). About 30 participants will receive this therapy, followed by standard chemotherapy and, for…

This Phase 3 trial is testing whether a higher dose of the chemotherapy drug cytarabine, given with standard drugs, improves survival for people with acute myeloid leukemia (AML) that has a specific genetic change called RUNX1-RUNX1T1. The study will enroll 300 adults aged 14 to …

This study tests an experimental oral medicine called CHM-029 in adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments, and that carries specific genetic changes (NPM1 mutations or KMT2A/NUP98 rearrangements). The main goals are to fin…

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…

This study is for adults with a certain type of acute myeloid leukemia (AML) who are in remission and planning a stem cell transplant. It compares a combination of two drugs, venetoclax and azacitidine, against standard high-dose chemotherapy as a 'consolidation' step before the …

This early-phase trial is testing a new type of immune cell therapy called FOLR1 CAR T cells for children aged 6 and under with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy involves taking a child's own immune cells, modifying them in…

This early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…

This study tests whether a combination of venetoclax and azacitidine works better than standard chemotherapy to keep high-risk acute myeloid leukemia (AML) from coming back before a stem cell transplant. About 216 adults who have already achieved remission after initial treatment…

This early-phase trial is testing whether infusing natural killer (NK) cells from a healthy donor, combined with low-dose interleukin-2 (IL-2), can safely help treat acute myeloid leukemia (AML) that has returned after a stem cell transplant. The study involves about 12 adults wi…

This phase 2 trial is testing whether adding an experimental drug called MAX-40279 to the standard combination of venetoclax and azacitidine can help treat newly diagnosed acute myeloid leukemia (AML) in people who are not healthy enough for intensive chemotherapy. The study incl…

This early-phase trial tests whether adding a radioactive antibody (225Ac-DOTA-daratumumab) to standard chemotherapy and targeted radiation can safely improve the conditioning regimen before a donor stem cell transplant. The study includes 15 adults with high-risk acute myeloid l…

This study tests a new drug called sonrotoclax combined with standard chemotherapy and other targeted medicines for adults newly diagnosed with acute myeloid leukemia (AML). About 205 participants will receive different treatments based on their genetic markers. The goal is to se…

This early-stage trial is testing an experimental oral drug, HPB-092, in people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The drug is designed to block two proteins, FLT3 and IRAK4, that help leukemia cells grow and survive. The stud…

This study tests the drug ponatinib in children aged 1 to 18 with advanced leukemias, lymphomas, or solid tumors that have come back or not responded to standard treatment. The goal is to find safe doses and see if the drug can shrink tumors or improve blood counts. About 70 chil…

This study tests a special cord blood transplant for people with high-risk blood cancers like leukemia and lymphoma. Participants get chemotherapy and radiation before the transplant to kill cancer cells and prepare the body. After the transplant, drugs are given to prevent the n…

This early-phase study tests whether specially engineered donor immune cells (TSC-100 or TSC-101) can safely reduce the risk of cancer returning after a stem cell transplant. About 75 adults with acute myeloid leukemia, myelodysplastic syndromes, or acute lymphoblastic leukemia w…

This early-phase study is testing an experimental oral drug called AZD3632 in about 84 people with advanced blood cancers (acute leukemias or myelodysplastic syndromes) that have certain genetic changes. The main goals are to check the drug's safety and find the right dose, while…

This phase 3 trial tests whether combining the targeted drug venetoclax with either a short course of decitabine or a modified DA regimen (daunorubicin and cytarabine) works better than the standard 3+7 DA regimen for adults newly diagnosed with acute myeloid leukemia. About 291 …

This study tests different chemotherapy doses and a drug to prevent graft-versus-host disease in adults aged 18 to 60 with newly diagnosed acute myeloid leukemia. Participants receive either idarubicin or daunorubicin during initial chemo, followed by high or intermediate doses o…

This phase 2 study tests whether a three-drug combination (ivosidenib, azacitidine, and venetoclax) followed by maintenance therapy with ivosidenib alone can prevent acute myeloid leukemia (AML) from coming back in patients with an IDH1 mutation. The trial enrolls 45 people aged …

This Phase 3 trial tests whether mocravimod, taken as a pill, can prevent acute myeloid leukemia (AML) from returning after a stem cell transplant. About 366 adults with high-risk AML will receive either mocravimod or a placebo for up to two years. The main goal is to see if the …

This early-phase trial tests whether combining tagraxofusp (a drug that targets CD123 on cancer cells) with azacitidine (a drug that helps bone marrow make normal cells) can safely prevent relapse in people with CD123-positive acute myeloid leukemia or myelodysplastic syndrome af…

This Phase 2 trial tests whether combining cladribine, low-dose cytarabine, and decitabine can help control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). About 160 older adults (60+) who haven't had prior intensive treatment will receive the drugs in c…

This phase 1 trial tests an oral chemotherapy drug (decitabine) alone or combined with other targeted drugs to prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. About 125 adults whose AML is under control but who are not ready for a s…

This study looks at whether a special treatment plan for children with acute myeloid leukemia (AML) can work well in Malawi, where resources are limited. About 30 children under 18 will receive a treatment guideline designed to balance curing the disease with manageable side effe…

This phase 1 trial tests a new drug called GTB-3650 for adults with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug is designed to connect natural killer cells—a type of immune cell—to cancer cel…

This phase 1 trial is testing whether adding the targeted drug pemigatinib after standard chemotherapy can help people with newly diagnosed acute myeloid leukemia (AML). Pemigatinib blocks a protein called FGFR that may fuel leukemia growth. The study will enroll 32 adults with i…

This study tests a new combination of three drugs (tagraxofusp, azacitidine, and venetoclax) for people with a type of acute myeloid leukemia (AML) that has returned or not responded to previous treatment. The goal is to see if this combination can help more patients achieve remi…

This trial tests a two-part treatment for people with acute myeloid leukemia (AML) that has not responded to standard therapy. First, patients receive a stem cell transplant from a healthy donor, but the stem cells are gene-edited to hide from the second treatment: specially engi…

This study tests whether giving children with leukemia a special type of donor immune cell (CD45RA-depleted) after a stem cell transplant can help their immune system recover faster and lower the risk of serious viral or fungal infections. The trial enrolls 50 children under 25 w…

This early-phase trial is testing a new treatment called CART123 for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. CART123 cells are specially engineered immune cells designed to find and kill leukemia cells. …

This early-phase study tests whether giving two drugs—ruxolitinib and azacitidine—after a stem cell transplant can safely prevent graft-versus-host disease (GVHD) and keep acute myeloid leukemia (AML) from coming back. About 40 adults with AML in remission will receive ruxolitini…

This early-phase trial is testing whether adding ruxolitinib to the standard drugs azacitidine and venetoclax is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. About 51 adults will receive the three-drug combination to find the…

This study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…

This study provides unlicensed cord blood units for transplant to children and adults with blood cancers, immune disorders, and other serious diseases. The goal is to see how well patients recover their white blood cells after the transplant. By making more cord blood units avail…

This phase 2 trial tests whether giving olutasidenib with azacitidine, followed by olutasidenib alone as maintenance, can keep acute myeloid leukemia (AML) with an IDH1 mutation from returning. The study enrolls 28 adults who have already achieved remission after initial treatmen…

This early-stage trial tests an experimental cell therapy called IBR733 for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy involves giving immune cells by vein in repeated cycles. The main goals are to check safety, …

This early-phase trial is testing whether adding the drug emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with leukemia or myelodysplastic syndrome receiving a reduced-intensity stem cell transplant. Emapalumab blocks a protein …

This study tests a combination of four drugs, called CLAG-GO, in adults whose acute myeloid leukemia (AML) has not responded to standard treatment or has come back after remission. Participants receive the drugs during a hospital stay, and if the cancer goes into remission, they …

This phase I trial tests whether adding the experimental drug iadademstat to two standard leukemia medications (azacitidine and venetoclax) is safe and tolerable for adults with newly diagnosed acute myeloid leukemia (AML) who cannot undergo intensive chemotherapy. Iadademstat bl…

This phase 2 trial tests whether adding vedolizumab to standard drugs (cyclophosphamide and tacrolimus) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia and myelodysplastic syndrome. GVHD occurs when donor immu…

This program provides expanded access to the experimental drug ziftomenib for adults with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). It is for patients who have exhausted standard …

This phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can improve outcomes for people with high-risk acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndromes. The study will enroll 3…

This phase II trial is for older adults with a specific type of acute myeloid leukemia (AML) that has IDH gene mutations. Researchers want to find out whether starting treatment with an IDH-targeted drug (ivosidenib or enasidenib) followed by standard therapy (azacitidine plus ve…

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This study tests a new drug called CCS1477 (inobrodib) in people with advanced blood cancers like leukemia, lymphoma, and myeloma that have not responded to standard treatments. The drug is given as an oral capsule, either alone or combined with other cancer medicines. The goal i…

This trial investigates whether luspatercept can treat anemia caused by chemotherapy in adults with low-risk acute myeloid leukemia (AML). Participants receive luspatercept injections after chemotherapy, and researchers monitor hemoglobin levels and safety. The study aims to find…

This early-phase trial is testing whether adding the drug daratumumab to standard chemotherapy can help adults aged 60 and older with a high-risk form of acute myeloid leukemia (AML). The main goal is to find the safest dose of daratumumab when given alongside chemotherapy. The s…

This early-stage trial tests a new treatment called ICG415 CAR-T cells for adults with acute myeloid leukemia that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, engineering them to recognize and attack leukemia cel…

This early-stage trial tests whether combining the drugs gilteritinib with ivosidenib or enasidenib is safe for people with acute myeloid leukemia (AML) that has returned or not responded to treatment. Participants must have specific gene mutations (FLT3 and IDH1 or FLT3 and IDH2…

This early-stage trial tests a new treatment called CD371-YSNVZ-IL18 CAR T cells for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find the safest dose and see what side effects occur. About 15 participants w…

This study tests whether combining two drugs, revumenib and mezigdomide, is safe for people with specific types of acute leukemia that have returned or not responded to prior therapy. About 52 participants aged 12 and older will take part. The goal is to find the best dose and se…

This early-phase trial tests a drug called CRD3874-SI, which activates the STING pathway to boost the immune system's ability to fight cancer cells. It is for people with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to f…

This study is testing a new approach for people with high-risk acute leukemias or myelodysplastic syndrome. Before a donor stem cell transplant, patients receive a radioactive antibody (211At-BC8-B10) designed to target and kill cancer cells while sparing healthy tissue. The goal…

This early-stage trial tests a special type of immune cell (CIML NK cells) combined with a low dose of IL-2 in people whose blood cancer (like AML or MDS) came back after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into remission.…

This early-stage trial tests an oral drug called AG-120 in people with advanced blood cancers, like acute myeloid leukemia, that have a specific IDH1 mutation. The study aims to find the safest dose and see if the drug can control the disease. About 291 participants will take the…

This study is testing a new way to do stem cell transplants for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). It combines stem cells from a half-matched donor (haploidentical) with cord blood, given at different times. The goal is to help …

This study combines three chemotherapy drugs (cladribine, idarubicin, cytarabine) with a targeted drug (quizartinib) to treat acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). It includes up to 80 adults who are newly diagnosed or whose cancer has returne…

This study tests a stem cell transplant method that removes certain immune cells (T-cells and B-cells) from the donor cells. The goal is to reduce graft-versus-host disease, a serious complication where donor cells attack the patient's body. The trial includes 20 children and you…

This early-stage trial is testing a new type of CAR-T cell therapy, called CT0890B, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses donor-derived immune cells that are engineered to target a protein called NKG2DL on …

This study tests a combination of two drugs, azacitidine (a standard chemotherapy) and APG1252 (a new targeted therapy), in people with high-risk acute myeloid leukemia (AML). The goal is to see if the combo is safe and can help control the disease. About 52 participants will be …

This study tests an experimental drug called ziftomenib in 6 Japanese adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drug is taken as a pill once daily. The goal is to see if it can help control the disease and how…

This early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…

This study tests whether taking oral azacitidine pills for up to six months can help prevent leukemia from returning in patients who are eligible for a stem cell transplant but cannot get one due to racial or socioeconomic disparities. The trial enrolls 12 adults with acute myelo…

This study looks at how the cancer drug ASTX727 (decitabine and cedazuridine) works in people with moderate or severe liver problems. About 27 adults with certain blood cancers or solid tumors will take the drug for up to 8 weeks. The goal is to understand how the liver affects t…

This early-stage study looks at how the body handles the cancer drug ASTX727 (decitabine and cedazuridine) in people with severe kidney problems compared to those with normal kidneys. It includes 18 adults with acute myeloid leukemia, myelodysplastic syndromes, or solid tumors. T…

This study tests a daily pill called ivosidenib in about 20 adults with a specific genetic form of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who cannot receive a stem cell transplant. The goal is to see if the drug can keep the cancer from coming ba…

This study tests an oral drug called olutasidenib in 3 Japanese patients whose acute myeloid leukemia (AML) has a specific IDH1 gene mutation and has not responded to or returned after other treatments. The main goal is to check safety, but researchers will also see if the drug c…

This study tests a new immune cell treatment called AdaptNK for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses specially selected natural killer cells from a donor, given after chemotherapy, to help control the…

This phase II trial is testing whether combining two drugs—CPX-351 (a chemotherapy) and venetoclax (a targeted therapy)—can help people with acute myeloid leukemia (AML) that has come back or not responded to prior treatment. About 52 adults will take part at MD Anderson Cancer C…

This study tests a combination of three drugs—venetoclax, ivosidenib, and azacitidine—in adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated AML). The goal is to see if this triple therapy can improve remission rates and survival compared to standard treat…

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…

This phase 2 trial tests whether adding venetoclax to standard intensive chemotherapy improves outcomes for adults with acute myeloid leukemia (AML). The study will enroll 380 patients aged 14 to 60 to see which genetic subtypes benefit most. Researchers hope to personalize treat…

This pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…

This study tests a combination of three drugs (gilteritinib, venetoclax, and azacitidine) in people newly diagnosed with acute myeloid leukemia (AML) who have a specific genetic change called FLT3 mutation. The goal is to see if this triple therapy can improve remission rates and…

This early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The drugs work by blocking different signals that …

This study tests whether a cord blood transplant can help children and young adults (up to age 26) with blood cancers like leukemia and lymphoma. Participants receive the transplant as their first or second treatment. The main goal is to see how many are cancer-free one year afte…

This study is testing a new targeted drug called crifortinib besylate (taken as a pill) combined with standard chemotherapy in adults who have just been diagnosed with acute myeloid leukemia (AML). The trial has two phases: first, finding the best dose, then testing it in a large…

This study tests a combination of five drugs (VABu) given before a stem cell transplant in people aged 60 and older with acute myeloid leukemia (AML). The goal is to see if this approach can help control the disease and improve survival. About 20 participants will receive the tre…

This early-phase trial tests a new cell therapy for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard treatment. The therapy uses the patient's own blood cells, armed with a special antibody to t…

This study compares a new treatment (venetoclax plus CACAG) to the standard chemotherapy for adults newly diagnosed with intermediate- or high-risk acute myeloid leukemia (AML). About 160 participants aged 14 to 75 will be randomly assigned to one of the two groups. The main goal…

This study tests a combination of two drugs—ivosidenib (a daily pill) and azacitidine (an injection or infusion)—in adults newly diagnosed with a type of acute myeloid leukemia (AML) that has an IDH1 gene mutation. The participants are not healthy enough for standard intensive ch…

This early-phase trial is testing a new approach for acute myeloid leukemia (AML) that combines a personalized vaccine made from the patient's own immune and leukemia cells, specially trained T-cells, and two standard chemotherapy drugs. The study aims to see if this combination …

This phase II trial tests different drug combinations to prevent graft-versus-host disease (GVHD) in 400 blood cancer patients receiving stem cell transplants from unrelated donors. Participants will receive either thymoglobulin or a combination of cyclophosphamide with other imm…

This study tests whether giving two common heart medications (a beta blocker and an ACE inhibitor) before and during intensive chemotherapy can prevent heart damage in people newly diagnosed with acute myeloid leukemia (AML). About 70 adults will be randomly assigned to receive t…

This early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…

This study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if the treatment can clear hidden cancer cells from the bone marrow and keep them away.…

This study is for adults newly diagnosed with a type of acute myeloid leukemia (non-M3). It tests whether adding silibinin, a natural compound from milk thistle that protects the liver, to standard chemotherapy can improve remission rates and survival. About 100 participants will…

This study tests a personalized vaccine made from a patient's own leukemia cells to help prevent the cancer from coming back. It is for adults with acute myeloid leukemia who are in remission after chemotherapy. The vaccine is designed to train the immune system to recognize and …

This study looks at whether menin inhibitors can help prevent leukemia from coming back in patients who have had a stem cell transplant. About 20 adults with certain genetic types of acute leukemia will take these drugs as maintenance therapy. Researchers will track how many pati…

This early-phase trial tests a new cell therapy for people with T-cell lymphoma or acute myeloid leukemia that has come back or not responded to standard treatments. The therapy uses immune cells (NK cells) from donated cord blood that are engineered to recognize and attack cance…

This study tests a new drug called HEC73543 (Clifutinib) against standard chemotherapy in 324 adults with a specific type of acute myeloid leukemia (FLT3-ITD) that has come back or not responded to first treatment. The goal is to see if the new drug helps people live longer and a…

This study tests whether a low-dose, weekly chemotherapy combination (decitabine and venetoclax) given after a bone marrow transplant can help prevent high-risk myeloid cancers like acute myeloid leukemia from coming back. About 20 participants will receive the treatment for up t…

This phase 3 trial tests two drugs, Thymoglobulin and Grafalon, to see which one better prevents graft-versus-host disease (GVHD) in patients aged 50-70 with acute myeloid leukemia or myelodysplastic syndrome. All participants receive a stem cell transplant from a matched unrelat…

This program provides galinpepimut-S, a cancer vaccine that aims to train the immune system to fight cancer cells, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have no other treatment options. It is for people who cannot join a cl…

This early-stage trial is testing whether adding the drug talazoparib to standard chemotherapy is safe for children and young adults up to age 21 whose acute myeloid leukemia (AML) has returned or not responded to treatment. About 34 participants will receive different doses to f…

This early-phase trial tests whether two drugs, ruxolitinib and abatacept, can prevent graft-versus-host disease (GVHD) and cytokine release syndrome in people receiving stem cell transplants from half-matched donors. About 41 adults with blood cancers will take these drugs aroun…

This early-phase trial is testing a new drug called imetelstat, combined with two standard chemotherapy drugs (azacitidine and venetoclax), in adults whose acute myeloid leukemia has returned or not responded to prior treatment. The study has two parts: first, finding a safe dose…

This study tests whether a new chemotherapy combination (TmBU) works better than the standard one (mBUCY) before a stem cell transplant in people with high-risk or hard-to-treat acute leukemia. About 48 patients aged 65 or younger will be randomly assigned to one of the two regim…

This study tests whether adding memory immune cells (CD45RO) to a stem cell transplant can help children fight off dangerous viral and fungal infections after the procedure. The transplant uses donor stem cells that have been stripped of certain cells to prevent graft-versus-host…

This study tests a new combination of drugs (cladribine, lisaftoclax, busulfan, and others) given before a stem cell transplant in 30 older adults (age 50+) with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. The goal is to see if this approach can re…

This phase 2 trial is testing a combination of three drugs—olutasidenib, venetoclax, and azacitidine—in adults aged 18-75 with newly diagnosed acute myeloid leukemia that has a specific IDH1 gene mutation. The study aims to see if this combo is safer and works better than standar…

This phase 2 trial tests a stem cell transplant using a milder chemo and radiation regimen for people with blood cancers like AML and MDS. The goal is to see if this approach improves survival at 100 days after transplant. Participants receive donor stem cells along with drugs to…

This early-stage trial tests a new treatment for adults with a specific type of acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack…

This study tests a combination of the targeted drug tagraxofusp with two chemotherapy drugs (cladribine and cytarabine) in 20 adults whose acute myeloid leukemia (AML) has come back or not responded to prior treatment. The goal is to find the safest dose and see how well the comb…

This study tests whether a stem cell transplant from a donor can help people with a high-risk type of acute myeloid leukemia (AML) stay cancer-free longer. Participants receive the transplant after initial chemotherapy. The trial tracks survival, relapse, and side effects in 90 n…

This study tests a precise type of radiation called proton total marrow irradiation (TMI) given before a stem cell transplant for people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see if adding TMI to standard chemotherapy is saf…

This early-phase study tests a new automated method (CliniMACS Prodigy) to select CD34 stem cells for patients with blood cancers who need a stem cell boost or second transplant. The goal is to reduce the risk of severe graft-versus-host disease (GVHD) while improving blood cell …

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once, aiming to prevent the cancer from escaping treatment. It is for adults with several types of blood cancers that have come back or not responded to standard treatments. Pa…

This study tests a device that removes specific immune cells from donated stem cells before transplant. The goal is to lower the risk of graft-versus-host disease, where donor cells attack the patient's body. Up to 90 children and young adults (ages 0-30) will receive these treat…

This study tests whether adding a precise, targeted form of radiation to the standard chemotherapy and stem cell transplant can kill more cancer cells in the bone marrow and reduce the chance of relapse. About 27 adults with acute leukemia or myelodysplastic syndrome (MDS) will r…

This trial tests whether a lower dose of total body irradiation (200 cGy) before a bone marrow transplant works as well as a standard higher dose (400 cGy) for people with acute leukemia. The goal is to see which dose leads to fewer severe side effects like graft-versus-host dise…

This study tests a special stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses stem cells that have had certain immune cells removed to lower the risk of graft-versus-host disease, a serious complication. About 70 participants will r…

This study tests a combination of five drugs (venetoclax, azacitidine, cytarabine, idarubicin, and G-CSF) as a first treatment for adults aged 18-70 with acute myeloid leukemia (AML) who are healthy enough for strong chemotherapy. The goal is to see how many patients achieve comp…

This early-stage trial is testing a new type of immunotherapy for people with CD30-positive blood cancers that have come back or not responded to treatment. The therapy uses a patient's own immune cells, which are collected, modified with a special antibody, and then given back t…

This Phase 2 trial tests whether adding venetoclax to a five-drug regimen (CACAG) works better than standard treatments for people whose acute myeloid leukemia has returned or not responded. About 200 adults aged 14 to 75 will be randomly assigned to one of the two approaches. Th…

This early-stage trial tests a new drug called C6 ceramide nanoliposome (Ceraxa) in 15 adults with acute myeloid leukemia that has come back or not responded to treatment. The drug is given by IV twice a week, and the main goal is to check safety and find the right dose. It is to…

This phase 2 trial tests whether a newer chemotherapy drug called CPX-351 works better than standard chemo for adults aged 50 and older with a hard-to-treat form of acute myeloid leukemia (AML). About 248 people will be randomly assigned to receive either CPX-351 or standard chem…

This early-phase trial tests a new drug called revumenib alongside standard chemotherapy and another targeted drug (midostaurin) for adults newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (NPM1 and FLT3 mutations). The study aims to find a safe…

This study tests a new oral drug called enzomenib (DSP-5336) in people with acute leukemia and certain other blood cancers that have not responded to standard treatments. The trial has two phases: first, finding the safest dose, and then checking how well it works alone or combin…

This early-phase trial tests whether giving patients extra gamma delta T-cells—a type of immune cell that can kill cancer—after a half-matched bone marrow transplant can improve outcomes. The study includes up to 38 adults with leukemia or myelodysplastic syndromes. The goal is t…

This early-stage study is testing a new drug called RPT1G in 24 adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) have not responded to standard treatments or have returned. The main goals are to see if the drug is safe and to find the best do…

This study tests a chemotherapy drug called CPX-351 (Vyxeos) as a maintenance treatment for adults with acute myeloid leukemia (AML) who are in remission but cannot have a bone marrow transplant. About 24 participants will receive up to 6 cycles of the drug to see what dose is sa…

This Phase 3 trial tests whether the drug gilteritinib is better than sorafenib at keeping leukemia from coming back in patients with a specific gene mutation (FLT3-ITD) after a stem cell transplant. About 594 adults and teens will take one of the two pills daily for up to 2 year…

This study tests whether adding two drugs, ruxolitinib and decitabine, to the standard chemotherapy given before a stem cell transplant can lower the chance of leukemia returning in high-risk patients. About 200 adults and teens with acute myeloid leukemia in first remission will…

This early-phase study tests an investigational drug called ziftomenib in adults with acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to find a safe dose and see if the drug can help prevent the cancer from coming back. About 22 participants will tak…

This study tests whether adding chidamide to the standard venetoclax and azacitidine (VA) regimen can help people with acute myeloid leukemia (AML) who did not improve after one cycle of VA alone. About 32 adults aged 18 or older who are not candidates for intensive chemotherapy …

This early-phase trial is testing whether combining two drugs—decitabine/cedazuridine (already approved for MDS) and the experimental drug defactinib—is safe and tolerable for people with high-risk myelodysplastic syndromes, certain acute myeloid leukemias, and chronic myelomonoc…

This study tests whether new drug combinations can better prevent graft-versus-host disease (GVHD) in people with blood cancers who receive a stem cell transplant from a mismatched unrelated donor. About 358 participants will get either the standard GVHD prevention or one of two …

This phase 2 trial tests a reduced-intensity chemotherapy regimen (fludarabine, busulfan, melphalan) before stem cell transplant in 61 patients aged 55 and older with myeloid cancers like AML, MDS, or CMML. The goal is to see if this gentler approach can improve disease-free surv…

This phase 3 trial tests whether adding the targeted drug venetoclax to standard chemotherapy (fludarabine and melphalan) before a donor stem cell transplant can improve outcomes for patients over 50 with acute myeloid leukemia or myelodysplastic syndrome. The study will compare …

This early-stage trial is testing an oral drug called BY002 in 18 adults with relapsed or refractory acute leukemia that has specific genetic changes (KMT2A rearrangements or NPM1 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shr…

This early-phase trial is testing a new drug called CBX-250 in people with certain blood cancers (like acute myeloid leukemia) that have come back or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 72 participants …

This study tests a cord blood transplant in children and young adults (up to age 21) with life-threatening blood cancers or non-cancer blood disorders who do not have a matched family donor. The goal is to see if this approach lowers the risk of death from treatment one year afte…

This study looks at whether people with acute myeloid leukemia (AML) who have responded well to a year of treatment with venetoclax and azacitidine can safely stop taking these drugs. Researchers will monitor 50 patients closely for signs of relapse and compare them to a similar …

This early-phase trial is testing an experimental treatment called CART84 for people with acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia (T-ALL) that has come back or not responded to treatment. The therapy uses a patient's own immune cells, modified in a lab…

This phase 2 trial is testing the drug dasatinib alone in adults with acute myeloid leukemia (AML) whose cancer did not respond to the usual combination of venetoclax and azacitidine. The main goal is to see if dasatinib can shrink the leukemia after two months of treatment. Abou…

This early-phase study tests a new treatment called ADCLEC.syn1 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goal is to find a safe dose that causes few side effects, and then see if it can help control…

This early-stage trial is testing whether a drug called olutasidenib can safely prevent blood cancers (AML, MDS, or CMML) from coming back after a donor stem cell transplant. About 15 adults with a specific gene mutation (IDH1) will take the drug daily for up to two years. The ma…

This early-stage trial tests a new treatment for acute myeloid leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack leukemia cells. The study aims to find the safest dose and un…

This early-phase trial tests a drug called revumenib in people with acute leukemia who have had a stem cell transplant. The drug targets a protein that helps leukemia cells grow. The study will check safety, find the best dose, and see if it can stop the cancer from coming back. …

This study is testing whether a combination of three drugs—venetoclax, a hypomethylating agent (azacitidine or decitabine), and low-dose cytarabine—can effectively treat adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (CEBPA-mutated AML) who are n…

This early-stage trial is testing a new drug called FHD-286 combined with two standard chemotherapy drugs (decitabine and venetoclax) in 33 people with acute myeloid leukemia that is either newly diagnosed with high-risk features or has returned after one prior treatment. The mai…

This phase 2 trial tests a three-drug combination (venetoclax, azacitidine, and homoharringtonine) followed by a stem cell transplant in 56 adults aged 18-55 with newly diagnosed, intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach improve…

This study tests whether specially trained immune cells from a half-matched donor can safely treat acute myeloid leukemia (AML) that has come back or not responded to standard treatment. About 20 people aged 2 and older will receive an infusion of these cells. The main goal is to…

This phase 2 trial tests whether two drugs, azacitidine and venetoclax, can eliminate or reduce measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who have completed standard chemotherapy and are scheduled for a donor stem cell transplant. The goal is t…

This phase 2 trial tests whether low-dose azacitidine can help maintain donor cell levels (chimerism) in patients with MDS, AML, or related blood cancers after an allogeneic stem cell transplant. About 43 adults whose donor cell levels are dropping will receive azacitidine for at…

This study is for children, teens, and young adults (ages 1 to 39) with acute leukemia that has come back or not gotten better with standard treatments. Researchers are testing whether combining two drugs—venetoclax and Vyxeos—is safe and tolerable. The goal is to find the best d…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests a new drug called STX-0712 in people with advanced types of blood cancer (CMML or AML) who have run out of standard treatments. The main goal is to find a safe dose and see how the body handles the drug. About 105 participants will take part in this early-phase t…

This early-phase trial tests whether the drug olutasidenib can safely help people with a specific genetic form of acute myeloid leukemia (IDH1-mutant AML) stay in remission after standard chemotherapy. About 15 participants will take the drug twice daily. The main goals are to se…

This phase 2 trial tests a personalized approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Instead of a one-size-fits-all chemotherapy and radiation regimen, doctors adjust the doses based on each patient's risk. The goal is to improve the…

This study tests a new treatment for adults with a specific type of acute myeloid leukemia (FLT3-ITD AML). The goal is to see if a combination of targeted drugs (gilteritinib, venetoclax, azacitidine) followed by high-dose chemotherapy can control the disease well enough to avoid…

This phase II trial is testing a combination of two drug regimens—VA (venetoclax and azacitidine) and low-dose CHA (cladribine, homoharringtonine, and cytarabine)—given in alternating cycles to newly diagnosed acute myeloid leukemia (AML) patients aged 60 or older who cannot tole…

This study tests whether replacing fludarabine with clofarabine in the chemotherapy given before a stem cell transplant can help more adults with acute myeloid leukemia (AML) stay alive longer. About 302 patients whose AML is in remission will be randomly assigned to one of two r…

This early-phase study tests a new drug called RJK-RT2831 in 71 adults with blood cancers. The main goals are to check safety, find the right dose, and see if the drug shows any early signs of working. Participants must be 18 to 74 years old and in good enough health to follow th…

This program offers early access to venetoclax, a targeted cancer pill, for people with certain blood cancers like leukemia or lymphoma who have no other good treatment options. A doctor must decide if the potential benefit outweighs the risks. The drug is not yet approved in all…

This study tests a drug called romiplostim N01 in 130 blood cancer patients receiving a stem cell transplant from a half-matched donor. The drug is given weekly for up to 4 weeks to help platelets recover faster, reducing the need for transfusions and bleeding risk. Half the pati…

This early-phase trial tests whether infusing specially designed immune cells can prevent blood cancer from coming back after a stem cell transplant. The cells target a specific protein (HLA-DPB1*04:01) found on many cancer cells and include a 'suicide switch' to turn them off if…

This study tests a new method to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk blood cancers who need a stem cell transplant from a half-matched donor. The approach combines specially enriched donor immune cells with a stem cell graft that h…

This early-phase trial tests a new type of immune therapy called CD70-CAR T cells in children and young adults up to age 21 with blood cancers that have come back or not responded to treatment. The therapy involves taking the patient's own immune cells, engineering them to recogn…

This early-phase trial is testing a new drug called CG009301 in adults with blood cancers like leukemia that have returned or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can help. About 45 participants will receive the drug by …

This early-stage study tests whether adding mitoxantrone to the usual venetoclax+azacitidine regimen can help adults with acute myeloid leukemia (AML) whose cancer did not respond or came back after initial treatment. About 30 participants will receive different doses to find the…

This early-stage trial is testing two oral drugs, CC-486 and venetoclax, together in people with acute myeloid leukemia (AML) that has relapsed or not responded to prior treatment. The main goal is to find the safest dose of CC-486 when combined with venetoclax, and to monitor si…

This early-stage trial tests a new drug called CLN-049 in about 60 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. CLN-049 is designed to help the body's immune cells attack cancer cells. The main goals …

This early-phase trial is testing whether adding the drug venetoclax to a standard chemotherapy regimen can help children and young adults whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 40 participants will receive different doses of venetoc…

This early-stage trial is testing a combination of two oral drugs—bomedemstat and venetoclax—in adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The main goal is to find the safest dose and check for side effects. Up to 18 participant…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This early-phase trial is testing whether adding the targeted drug venetoclax to standard chemotherapy can safely treat adults newly diagnosed with acute myeloid leukemia or advanced myelodysplastic syndrome. About 99 participants will receive different doses of venetoclax alongs…

This early-phase study tests whether a special cell therapy called T-allo10 can safely help rebuild the immune system in children and young adults (up to age 45) with blood cancers who have received a stem cell transplant. The treatment is given after the transplant to speed up r…

This early-stage trial is testing an experimental oral drug called MRX-2843 in adolescents and adults whose acute leukemia (AML, ALL, or mixed phenotype) has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and s…

This phase 2 trial tests a low-dose weekly schedule of two drugs, decitabine and venetoclax, in people with myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), or chronic myelomonocytic leukemia (CMML). The goal is to see if this gentler approach reduces treatment dela…

This study tests whether sulforaphane, a compound found in broccoli sprouts, can help blood cells recover faster after a cord blood transplant in adults with leukemia or related blood cancers. The trial will involve 36 patients and focus on safety and how quickly neutrophils (a t…

This early-stage trial tests a new oral drug, ZE46-0134, in 150 adults whose acute myeloid leukemia (AML) has come back or not responded to standard treatment. The study focuses on people with specific gene changes (FLT3 or spliceosome mutations). The main goals are to check safe…

This phase 2 trial tests a combination of three drugs—venetoclax, cladribine, and low-dose cytarabine—in 68 adults aged 16-70 with acute myeloid leukemia that has returned or not responded to prior treatment. The goal is to see if this cocktail can shrink or eliminate leukemia ce…

This phase II trial tests whether the drug chidamide can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 134 adults with high-risk AML who are in remission after transplant will either take chidamide pills or receive standard observa…

This early-stage study tests a new treatment called SC-DARIC33 for children and young adults up to age 30 whose acute myeloid leukemia (AML) has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in the lab to bett…

This early-stage trial tests a new treatment called MT-401-OTS for people with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor immune cells specially trained to attack cancer, and is given as a one-time infusion. The main goals are t…

This study tests a new drug called ARD103 in adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or not responded to standard treatments. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink or c…

This study tests whether a genetic test can help decide which leukemia patients need a strong antifungal drug (posaconazole) to prevent serious mold infections during chemotherapy. About 410 adults with acute myeloid leukemia will be randomly assigned to receive the drug or a pla…

This early-phase study tests whether specially engineered immune cells (CAR-T cells) that target a protein called CD19 are safe for adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. Only patients whose leukemia cells show high levels of CD…

This study tests whether giving extra natural killer (NK) cells from a donor can safely help prevent leukemia or MDS from coming back after a stem cell transplant. About 10 adults with acute myeloid leukemia or myelodysplastic syndromes who don't have a fully matched donor will r…

This early-stage trial tests a new type of immune cell therapy called LILRA6 CAR-T for people with acute myeloid leukemia that has come back or not responded to standard treatment. The therapy uses a patient's own T cells, modified in a lab to target leukemia cells. The study wil…

This clinical trial tests whether infusions of donor natural killer (NK) cells, given before and after a stem cell transplant, can safely prevent leukemia from coming back in children and young adults with hard-to-treat acute leukemia. The study enrolls 15 patients aged 0 to 25 w…

This study observes 250 adults with a specific genetic subtype of acute myeloid leukemia (AML) who received the targeted drug Ivosidenib through a compassionate use program in France. Researchers will track survival and treatment response in patients receiving the drug as a first…

This global phase 3 trial tests whether adding the experimental drug lisaftoclax to standard azacitidine helps older adults with newly diagnosed acute myeloid leukemia (AML) live longer. About 486 participants who cannot have intensive chemotherapy will receive either the combo o…

This study tests whether a combination of two drugs (venetoclax and low-dose cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. Participants are 18–60 years old, have achieved complete remission after initial chemotherapy, and are not able to …

This study is testing a specific set of four chemotherapy blocks in children (0-18 years) who have both acute myeloid leukemia (AML) and Down syndrome. The goal is to see if this tailored treatment can improve long-term survival and reduce harsh side effects compared to past appr…

This phase 2 trial tests whether adding two drugs, ruxolitinib and abatacept, to standard transplant care can prevent graft-versus-host disease (GVHD) in 60 patients with high-risk myeloid cancers like AML and MDS. Participants receive a stem cell transplant from a partially matc…

This program offers extra stem cells from a half-matched family donor to patients who are getting a cord blood transplant for serious blood cancers or immune disorders. The goal is to help the bone marrow recover more quickly while the cord blood cells take over permanently. It i…

This study tests whether infusing special immune cells called γδ T cells can prevent relapse in people with high-risk acute myeloid leukemia (AML) who have had a stem cell transplant. The trial will enroll 40 adults aged 18 to 65. The main goal is to see if the treatment improves…

This study tests a stem cell transplant approach for people with Fanconi Anemia who don't have a perfectly matched donor. The goal is to see if using lower doses of chemotherapy before the transplant can reduce serious side effects. About 70 participants will receive a transplant…

This study tests whether using a simple early warning score (NEWS) to quickly move high-risk blood cancer patients to the ICU can reduce deaths and organ failure. Over 2,200 adults receiving intensive chemotherapy or stem cell transplants will take part across ten hospitals. Half…

This study is testing whether adding two targeted drugs, midostaurin and gemtuzumab ozogamicin, to standard chemotherapy can help people with newly diagnosed acute myeloid leukemia (AML) who have certain genetic changes. About 214 participants will receive the combination in two …

This early-phase trial tests a combination of two chemotherapy drugs—Vyxeos (a liposomal form of daunorubicin and cytarabine) and clofarabine—in 25 children and young adults (ages 1-21) with relapsed or refractory acute myeloid leukemia (AML). The main goal is to find the safest …

This study is testing whether tracking leukemia stem cells in the blood during the first week of treatment can predict how well a patient with acute myeloid leukemia (AML) will respond. Currently, doctors check treatment effectiveness with a bone marrow biopsy after about a month…

This study looks at a new genetic test called Caris Chromoseq for people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, or myeloproliferative neoplasms). The test scans the entire genome to help classify the cancer and guide risk assessment. Researc…

This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…

This phase 3 trial tests whether xylitol dental wipes can reduce bloodstream infections in children with acute myeloid leukemia (AML). Xylitol, a natural sugar that limits mouth bacteria growth, is applied via wipes during chemotherapy. The study will compare infection rates betw…

This study looks at whether a low dose of the antifungal drug liposomal amphotericin B can prevent serious fungal infections in adults with blood cancers or who have had stem cell transplants and have a prolonged low white blood cell count (neutropenia). The trial enrolls 30 pati…

This early-phase trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV) and prevent active infection after a half-matched stem cell transplant. About 46 people with various blood cancers will take part…

This phase 2 trial tests a vaccine called CMV-MVA Triplex, given to stem cell donors before they donate. The goal is to boost the donor's immunity against cytomegalovirus (CMV), which can then be passed to the transplant patient. Researchers hope this will prevent CMV infection i…

This study tests a program called EASE that combines psychological support with regular symptom checks and early access to palliative care. Researchers want to see if it reduces traumatic stress and physical symptoms in people newly diagnosed with acute leukemia. Half of the 266 …

This study tests a home-based exercise program called CAREFit-BMT for people with high-risk acute myeloid leukemia who are about to have a stem cell transplant. The program includes aerobic and strength training to improve heart function before the procedure. Researchers will enr…

This trial tests two digital platforms, one for children with cancer and one for their parents, designed to improve communication with healthcare providers and address physical, emotional, social, and spiritual needs during treatment. Researchers will recruit 120 families of chil…

This study tests an online music therapy program that combines mindfulness and music to help people recovering from stem cell transplants for blood cancers. Researchers want to see if it can improve quality of life, reduce pain, fatigue, anxiety, and depression, and possibly spee…

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…

This study tests whether tranexamic acid (TXA), a drug that prevents blood clots from breaking down, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 outpatients receiving less-intensive chemotherapy will be rando…

This study tests whether regular massage therapy can improve sleep for children aged 12-21 who are hospitalized for cancer treatment or stem cell transplant. Seventy participants will either receive standard care or a 20-30 minute massage five days a week for three weeks. Sleep w…

This study looks at whether using a simple quality-of-life questionnaire to decide when to give blood transfusions can reduce the number of transfusions needed for people with advanced myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who are receiving palliative ca…

This study tests whether giving blood transfusions at home is practical and acceptable for cancer patients who need regular transfusions. About 30 adults with blood cancers or bone marrow failure will receive 1-5 blood product units at home. Researchers will track how often trans…

This study tests a digital app called DREAMLAND designed to improve quality of life and emotional well-being for adults with acute myeloid leukemia (AML) undergoing intensive chemotherapy. About 200 hospitalized patients will either use DREAMLAND or a standard wellness app. Resea…

This study tests a new way to screen patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) by analyzing their bone marrow and blood for specific biomarkers. The goal is to quickly match patients with a treatment trial that targets their cancer's unique mark…

This study looks at whether adults with acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy are willing to let a computer randomly assign them to either lower- or higher-intensity treatment. The goal is to see if this approach is acceptable to patients…

This study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia or MDS talk to their doctors about their care wishes. The program also helps them fill out advance directive forms. Researchers want to see if it improves communication and reduce…

This study follows people of all ages who have or may have a RUNX1 gene variant, which can cause bleeding problems and increase the risk of blood cancers. Researchers will collect medical history, blood samples, and bone marrow over many years to understand how the condition deve…

Researchers are building a registry to collect long-term health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia. The study gathers details on blood counts, bone marrow tests, genetic changes, and treatments. By following these pat…

This study looks at 60 adults with acute myeloid leukemia or related blood cancers who are receiving a gentler type of chemotherapy. Researchers will measure certain proteins in the blood to see if they can predict how well the treatment works. The goal is to better understand wh…

This study is collecting blood, bone marrow, and leftover tissue samples from 550 people with acute myeloid leukemia or follicular lymphoma. Researchers will analyze the samples to find genetic markers that may predict how well treatments work or why some stop working. The goal i…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study looks at the long-term health of people with Down syndrome who have been treated for acute leukemia. Researchers want to understand what chronic health problems survivors may face and what factors contribute to them. The goal is to create better follow-up care guidelin…

This study screens children and young adults up to age 22 whose leukemia has returned or is hard to treat. By testing their blood and bone marrow, doctors can identify specific genetic markers to match them with the most promising experimental treatments. The goal is to build a r…

This study explores whether combining a drug sensitivity test with detailed genetic profiling can help doctors recommend the best treatment for each patient with relapsed or refractory acute myeloid leukemia (AML). Researchers will take extra blood or bone marrow samples from 18 …

This observational study will follow 4,000 people whose acute myeloid leukemia has returned or not responded to treatment. Researchers will collect data from routine care to understand survival rates and treatment patterns over up to 4 years. No new drugs are being tested; the go…

This study looks at a new method to measure special immune cells called iNKT cells in the blood of patients who have had a stem cell transplant. These cells may help predict serious complications like graft-versus-host disease (GvHD) and relapse. Researchers will test 75 adults w…

This study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …

This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…

This study looks at whether measuring the amount of venetoclax in the blood can help doctors give the right dose to people with newly diagnosed acute myeloid leukemia (AML). Currently, everyone gets the same dose, but drug levels vary a lot between patients. The goal is to find a…

This early-stage study with 10 adults with acute leukemia looks at how the body absorbs, breaks down, and gets rid of the drug bleximenib. Participants take a radioactive version of the drug so researchers can track it in urine and stool. The goal is to understand the drug's path…

This study looks at whether screening adults with leukemia for social needs (like housing or food) and offering early social work help is practical and helpful. About 80 newly diagnosed patients will either get the screening and consultation or usual care. The goal is to see if t…

This study is collecting genetic samples from 50 adults with newly diagnosed acute myeloid leukemia (AML) who are starting treatment with azacitidine and venetoclax. Researchers want to see if certain genetic variations are linked to severe side effects or how well the drugs work…

This early study tests whether a single injection of motixafortide can help reveal tiny amounts of leukemia cells that remain after initial chemotherapy in people with acute myeloid leukemia (AML). Ten adults who have completed 1-2 cycles of treatment will receive the drug and th…

This study follows people with myelodysplastic syndromes (MDS) for up to 20 years to understand how the disease changes over time. Researchers will collect blood, bone marrow, and other samples from 1,100 participants, including healthy donors. The goal is to learn more about MDS…

This study looks at whether extra financial help (called financial navigation) can reduce money-related stress and improve quality of life for people being treated for acute myeloid leukemia (AML). About 120 adults aged 18-64 starting intensive chemotherapy will be split into two…

This study collects blood, bone marrow, skin, saliva, and stool samples from up to 1,000 healthy volunteers aged 18 and older. The samples will be stored in a database for researchers to compare with samples from people who have myelodysplastic syndromes (MDS), a group of blood d…

This study aims to safely collect health information like heart rate and activity levels from cancer patients using devices like smartphones and wearables. Researchers will use this data to learn more about how it relates to cancer diagnosis, treatment response, and risk factors.…

This pilot study is testing whether fecal microbiota transplantation (FMT) — giving processed stool from a healthy donor via enema — is safe and doable in 20 patients with lymphoma or leukemia who are receiving CAR-T therapy or stem cell transplants. The goal is to see if at leas…

This study follows people with a gene change (DDX41) that raises the risk of blood cancers like MDS and AML, along with their family members. Researchers will collect health information and samples over 10 years to learn how these inherited risks lead to cancer. No treatment is g…

This study tests a special tool called UR-GOAL that helps older adults (age 60+) with newly diagnosed acute myeloid leukemia and their caregivers make informed treatment choices. About 1,020 participants will be randomly assigned to use the tool or receive standard information. T…

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This observational study examines a specific group of patients with a type of acute myeloid leukemia (AML) that has an NPM1 mutation. Researchers want to see if a particular subset, called APL-like, is linked to early blood vessel problems like bleeding or clots. The study will l…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study looks at blood cells from 20 adults with acute myeloid leukemia (AML) whose cancer returned after a stem cell transplant. All participants have specific genetic changes (NPM1 mutations or KMT2A rearrangements) and are being treated with a menin inhibitor. Researchers w…

This study collects blood and bone marrow samples from 80 adults newly diagnosed with acute myeloid leukemia (AML). Researchers will measure inflammasome activity before and after standard chemotherapy to see if it relates to how well the treatment works. The goal is to better un…

This study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…

This study looks at how the body processes venetoclax when the tablet is crushed and mixed into a liquid. It includes 30 children and young adults with blood cancers who already take venetoclax this way. The goal is to measure drug levels in the blood and spinal fluid to ensure t…

This study tracks T-cell changes in 250 acute myeloid leukemia patients receiving a stem cell transplant. By analyzing blood samples with advanced gene sequencing, researchers hope to understand if the immune system plays a key role in recovery and complications. The goal is to f…

This study is creating a collection of blood and bone marrow samples from 1,000 adults with acute myeloid leukemia, acute lymphoblastic leukemia, or high-risk myelodysplastic syndrome. The samples will be used by researchers to better understand these diseases and find new ways t…

This study is looking at substances in the bone marrow of adults with acute myeloid leukemia (AML) to see if they can predict how well chemotherapy will work. Researchers will measure certain factors in bone marrow samples from 405 newly diagnosed AML patients and compare them to…

This study looks at genetic changes in people with early-stage blood cancers or conditions that may lead to cancer. Researchers will analyze blood, bone marrow, or cheek cell samples from up to 10,000 participants to find DNA errors linked to cancer risk and progression. The goal…

This study looks at how the drug venetoclax behaves in the bodies of 100 adults with acute myeloid leukemia (AML). Researchers will take extra blood samples to measure drug levels and see how they relate to treatment success. The study does not change the patient's regular care a…

This study is not a treatment itself but a research method. It will collect data from nearly 2,000 older adults (60-75) with acute myeloid leukemia (AML) to compare a new drug combination (venetoclax plus decitabine) against standard intensive chemotherapy. Using AI and statistic…

This study tests whether a special PET scan (18F FLT) can detect signs of leukemia or myeloma after treatment. About 60 people aged 4 to 80 with relapsed or hard-to-treat blood cancers will get the scan before and after therapy. Researchers will compare the scan results with stan…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This registry study is collecting medical information and biological samples from 15,000 adults with acute myeloid leukemia (AML) across 60 German hospitals. Researchers aim to track patient outcomes, treatment patterns, and disease characteristics to better understand AML. No ne…

This observational study looks at whether leukemia stem cells can predict if acute myeloid leukemia (AML) with MLL rearrangement will come back. Researchers will measure these stem cells in bone marrow samples taken during regular check-ups. The goal is to improve relapse predict…

This study aims to understand exactly how the drug interferon attacks cancer stem cells in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will analyze blood samples from 80 adults to see why some patients respond well while others do not. T…

This study gathers basic health information from 2000 people receiving stem cell transplants for blood cancers or immune disorders. The goal is to track survival and complications to help doctors and researchers improve future treatments. Participants must be getting a standard t…

This study collects stored cord blood from 300 children diagnosed with leukemia and checks for the same cancer mutations found in their tumor samples. Researchers want to understand how and when these mutations first appear before birth. The goal is to eventually develop a screen…

This study is for 80 adults with blood cancers like MDS or AML who are starting treatment. Participants wear a smartwatch and answer questionnaires to track their activity, symptoms, and quality of life. The goal is to help doctors better understand when patients need blood trans…

This study is testing a new, highly sensitive blood test (digital PCR) to find tiny amounts of leukemia cells that remain after a stem cell transplant in people with acute myeloid leukemia (AML). The goal is to see if this test can predict a relapse earlier than current methods. …

This study is for people with neuroendocrine tumors who are about to receive or have already received peptide receptor radionuclide therapy (PRRT). Researchers want to find out if certain genetic changes in the blood can predict who might later develop myelodysplastic syndrome (M…

This study looks at memory, concentration, and language problems caused by chemotherapy in people with blood cancers like leukemia and lymphoma. Researchers will compare 120 patients to their healthy relatives using tests and questionnaires before and after treatment. The goal is…

This study is gathering information from 25 adults with breast, lung, ovarian, multiple myeloma, or acute myeloid leukemia who are on active treatment. Participants fill out a short online survey each week for at least 12 weeks to report how they are feeling. The goal is to build…

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This study is collecting genetic and drug sensitivity data from 300 children with leukemia to better understand why some cases relapse and how to target them more precisely. Researchers will analyze tumor DNA, gene activity, and test drugs on patient cells in the lab. The goal is…

This study aims to find specific epigenetic markers in the blood of elderly patients with acute myeloid leukemia (AML). Researchers will analyze DNA from blood samples of 30 AML patients and compare them to samples from healthy older adults undergoing heart surgery. The goal is t…

This study is a registry that collects information from up to 50,000 adults with acute myeloid leukemia (AML) or related blood cancers. Researchers will track patients' genetics, treatment responses, and long-term outcomes over up to 10 years. The goal is to better understand the…

This study is looking at whether certain carbohydrates in food, called FODMAPs, are related to graft-versus-host disease (GVHD) in people who have had a bone marrow transplant. GVHD is a common complication where donor cells attack the patient's body. Researchers will track 100 t…

This study looks at whether detecting leftover leukemia stem cells in the blood or bone marrow after chemotherapy can better predict if a child's leukemia will come back. About 283 children with newly diagnosed acute myeloid leukemia will be followed. The goal is to improve relap…

This study follows 150 people with a GATA2 gene mutation to learn what factors predict if they will develop serious blood cancers like MDS or AML. Researchers will collect blood and bone marrow samples over 5 years and also review past data from 100 other patients. The goal is to…

This study creates a registry of 5,000 adults aged 50 and older with blood cancers like multiple myeloma and lymphoma. Researchers will track frailty, muscle loss, and other age-related health issues to better understand this group's needs. The goal is to gather information that …

This study aims to develop a faster way to test new drug combinations for acute myeloid leukemia (AML). Researchers will take blood and bone marrow samples from 25 adults with AML and grow their cancer cells in special mice. They will then test how well standard treatments work i…

This study looks at families who carry a change in the DDX41 gene, which may raise the risk of blood cancers like leukemia. Researchers will collect health questionnaires and saliva samples from up to 910 people to track who develops blood problems and when. The goal is to better…

This study looks at how much venetoclax is in the blood of people with acute myeloid leukemia (AML) who are in remission and still receiving treatment. The goal is to see if higher drug levels are linked to more severe side effects, like low white blood cell counts. By understand…

This study looks at bone marrow cells from children with acute leukemia and compares them to cells from children without blood diseases. The goal is to understand why some leukemias relapse or resist treatment. Researchers will measure how these cells use energy and handle stress…

This study follows 5,000 adults with acute myeloid leukemia (AML) in French hospitals to see how they are actually treated and how they fare over time. Researchers will collect data on treatments, survival, and disease progression for up to 10 years. The goal is to understand rea…

This study is a registry that tracks patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will collect information on recovery, complications, and costs over time. The goal is to understand how high altitude affect…

This study aims to develop special lab tests that can find tiny numbers of cancer cells left behind after treatment for acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). Researchers will follow 400 patients over time to see if these tests can predict whic…

This study follows 1,000 people who previously received an experimental cell therapy (TSC-100 or TSC-101) for blood cancers like leukemia. Researchers will track side effects and survival for up to 15 years to see if the treatment remains safe and effective over time. No new trea…